Anthropic acquires biotech startup Coefficient Bio for $400 million in stock

Anthropic has acquired Coefficient Bio, a stealth biotech AI startup, for $400 million in stock, according to The Information and independent tech journalist Eric Newcomer. It is the company's first major acquisition beyond traditional AI infrastructure, and a clear sign that Anthropic sees the life sciences as the next big arena for its technology. Until the very end, Coefficient Bio stayed almost invisible to the public: the startup operated in stealth mode, which is unusual in itself for a deal of this size.

Nothing is publicly known about its team, its specific work, or the stage of its product. $400 million in stock is a hefty sum for a company the market knew essentially nothing about until the deal closed. That suggests Anthropic was buying a team and technology first, not a finished product with users.

The acquisition fits a broader industry trend: major AI labs are actively looking for ways to apply their models beyond conventional text and multimodal tasks. Biology and medicine are among the most promising targets, from protein structure prediction and drug molecule design to genomic data analysis and modeling cellular processes. All of this involves huge volumes of complex, structured data, which is exactly what modern AI systems handle especially well.

Google DeepMind has already shown what AI can do here with AlphaFold, a system that solved the problem of predicting the three-dimensional structure of proteins, long considered one of biology's key unsolved problems for decades. Since then, bio-AI has grown rapidly: new startups are raising generous funding, and the big players are building long-term strategies for a presence in the sector. Anthropic positions itself as a company with a particular focus on the safety and reliability of AI systems.

That makes biomedicine an especially logical move: in medicine and biology, mistakes are critically costly and the bar for verifiable results is as high as it gets, so demand for responsible AI is particularly strong. Coefficient Bio apparently worked in exactly this space, at the intersection of deep machine learning and biological research. The deal structure, $400 million in stock rather than cash, is also telling.

The startup's founders and investors get a stake in Anthropic instead of an immediate payout. The format points to mutual confidence: the Coefficient Bio team is betting on Anthropic's continued growth, while Anthropic keeps its cash for operating expenses and future investments. With Anthropic's latest valuation at around $61 billion, that stake is an attractive long-term holding.

What does this mean for the market as a whole? Big AI companies are entering a phase of active acquisitions, and biotech is becoming one of their priorities. OpenAI, Google DeepMind, and other well-capitalized players are highly likely to follow Anthropic with similar moves.

For startups working at the intersection of AI and the life sciences, that means more interest from strategic buyers and higher valuations as early as their first funding rounds. Details on Coefficient Bio's team and tech stack are expected in an official statement from Anthropic in the near future.